The CheckMate026 study conducted a comparison between nivolumab and platinum-based chemotherapy in patients diagnosed with stage IV NSCLC who had PD-L1 expression levels greater than 5% in their tumor cells and did not have EGFR- or ALK-activating mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.